These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 36146629)

  • 21. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.
    Ghasemi M; Abbasi L; Ghanbari Naeini L; Kokabian P; Nameh Goshay Fard N; Givtaj N
    Front Immunol; 2022; 13():950079. PubMed ID: 36703982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
    Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
    Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current landscape and perspective of oncolytic viruses and their combination therapies.
    Su Y; Su C; Qin L
    Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
    Zhang Y; Li Y; Chen K; Qian L; Wang P
    Cancer Cell Int; 2021 May; 21(1):262. PubMed ID: 33985527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
    Oh CM; Chon HJ; Kim C
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.
    Ricordel M; Foloppe J; Antoine D; Findeli A; Kempf J; Cordier P; Gerbaud A; Grellier B; Lusky M; Quemeneur E; Erbs P
    Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29996551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.
    Malfitano AM; Somma SD; Prevete N; Portella G
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31636245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deletion of
    Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
    EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic Viruses and the Immune System: The Dynamic Duo.
    Lemos de Matos A; Franco LS; McFadden G
    Mol Ther Methods Clin Dev; 2020 Jun; 17():349-358. PubMed ID: 32071927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review: Oncolytic virotherapy, updates and future directions.
    Fountzilas C; Patel S; Mahalingam D
    Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept.
    Mahasa KJ; Ouifki R; Eladdadi A; Pillis L
    Math Biosci Eng; 2022 Mar; 19(5):4429-4457. PubMed ID: 35430822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.
    Rahman MM; McFadden G
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.
    Bastin D; Walsh SR; Al Saigh M; Wan Y
    Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.